-
Upstream Bio NASDAQ:UPB At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases.
Location: Waltham, Massachusetts, United States | Website: https://upstreambio.com/ | Industry: Pharmaceutical and Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-18.57M
Cash
470.5M
Avg Qtr Burn
-14.79M
Short % of Float
13.06%
Insider Ownership
19.78%
Institutional Own.
87.70%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|